Literature DB >> 23378893

Therapeutic challenges in advanced renal cell carcinoma.

Daniel C Cho1.   

Abstract

The therapeutic landscape of advanced renal cell carcinoma has grown increasingly more complex with the recent approval of several molecularly targeted agents. While researchers focus on developing predictive algorithms and identifying novel therapeutic targets and agents, clinical practitioners continue to face many practical challenges when determining therapeutic strategies for individual patients. This review will discuss several of these challenges including patient selection strategies, sequential therapy, optimal dose and schedule of various drugs, and therapeutic options for patients with nonclear-cell renal cell carcinoma.

Entities:  

Year:  2013        PMID： 23378893      PMCID： PMC3558941          DOI： 10.2217/cpr.12.77

Source DB:  PubMed          Journal:  Clin Pract (Lond)        ISSN： 2044-9038


  29 in total

1.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Authors:  Robert J Motzer; Bernard Escudier; Stephane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

4.  Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.

Authors:  Brian I Rini; Joan H Schiller; John P Fruehauf; Ezra E W Cohen; Jamal C Tarazi; Brad Rosbrook; Angel H Bair; Alejandro D Ricart; Anthony J Olszanski; Kristen J Letrent; Sinil Kim; Olivier Rixe
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

5.  A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.

Authors:  Frank Stenner; Rahel Chastonay; Heike Liewen; Sarah R Haile; Richard Cathomas; Christian Rothermundt; Raffaele D Siciliano; Susanna Stoll; Alexander Knuth; Tomas Buchler; Camillo Porta; Christoph Renner; Panagiotis Samaras
Journal:  Oncology       Date:  2012-06-02       Impact factor: 2.935

Review 6.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

7.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Authors:  Olivier Rixe; Ronald M Bukowski; M Dror Michaelson; George Wilding; Gary R Hudes; Oliver Bolte; Robert J Motzer; Paul Bycott; Katherine F Liau; James Freddo; Peter C Trask; Sinil Kim; Brian I Rini
Journal:  Lancet Oncol       Date:  2007-10-23       Impact factor: 41.316

8.  Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Authors:  Arkadiusz Z Dudek; Jakub Zolnierek; Anu Dham; Bruce R Lindgren; Cezary Szczylik
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

9.  Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Authors:  Brian I Rini; George Wilding; Gary Hudes; Walter M Stadler; Sinil Kim; Jamal Tarazi; Brad Rosbrook; Peter C Trask; Laura Wood; Janice P Dutcher
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

10.  Sunitinib efficacy against advanced renal cell carcinoma.

Authors:  Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450
View more
  1 in total

1.  Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC.

Authors:  Krishnendu Pal; Vijay Sagar Madamsetty; Shamit Kumar Dutta; Debabrata Mukhopadhyay
Journal:  Int J Nanomedicine       Date:  2019-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.